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Abstract: BACKGROUND: The cancer-anorexia-cachexia syndrome (CACS) negatively affects survival
and therapy success in cancer patients. Inflammatory mediators and tumour-derived factors are thought
to play an important role in the aetiology of CACS. However, the central and peripheral mechanisms
contributing to CACS are insufficiently understood. The area postrema (AP) and the nucleus tractus
solitarii are two important brainstem centres for the control of eating during acute sickness conditions.
Recently, the tumour-derived macrophage inhibitory cytokine-1 (MIC-1) emerged as a possible mediator
of cancer anorexia because lesions of these brainstem areas attenuated the anorectic effect of exogenous
MIC-1 in mice. METHODS: Using a rat hepatoma tumour model, we examined the roles of the AP
and of vagal afferents in the mediation of CACS. Specifically, we investigated whether a lesion of the AP
(APX) or subdiaphragmatic vagal deafferentation (SDA) attenuate anorexia, body weight, muscle, and
fat loss. Moreover, we analysed MIC-1 levels in this tumour model and their correlation with tumour size
and the severity of the anorectic response. RESULTS: In tumour-bearing sham-operated animals mean
daily food intake significantly decreased. The anorectic response was paralleled by a significant loss of
body weight and muscle mass. APX rats were protected against anorexia, body weight loss, and muscle
atrophy after tumour induction. In contrast, subdiaphragmatic vagal deafferentation did not attenuate
cancer-induced anorexia or body weight loss. Tumour-bearing rats had substantially increased MIC-1
levels, which positively correlated with tumour size and cancer progression and negatively correlated with
food intake. CONCLUSIONS: These findings demonstrate the importance of the AP in the mediation of
cancer-dependent anorexia and body weight loss and support a pathological role of MIC-1 as a tumour-
derived factor mediating CACS, possibly via an AP-dependent action.
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Abstract
Background The cancer-anorexia-cachexia syndrome (CACS) negatively affects survival and therapy success in cancer pa-
tients. Inflammatory mediators and tumour-derived factors are thought to play an important role in the aetiology of CACS.
However, the central and peripheral mechanisms contributing to CACS are insufficiently understood. The area postrema
(AP) and the nucleus tractus solitarii are two important brainstem centres for the control of eating during acute sickness con-
ditions. Recently, the tumour-derived macrophage inhibitory cytokine-1 (MIC-1) emerged as a possible mediator of cancer an-
orexia because lesions of these brainstem areas attenuated the anorectic effect of exogenous MIC-1 in mice.
Methods Using a rat hepatoma tumour model, we examined the roles of the AP and of vagal afferents in the mediation of
CACS. Specifically, we investigated whether a lesion of the AP (APX) or subdiaphragmatic vagal deafferentation (SDA) attenu-
ate anorexia, body weight, muscle, and fat loss. Moreover, we analysed MIC-1 levels in this tumour model and their correlation
with tumour size and the severity of the anorectic response.
Results In tumour-bearing sham-operated animals mean daily food intake significantly decreased. The anorectic response
was paralleled by a significant loss of body weight and muscle mass. APX rats were protected against anorexia, body weight
loss, and muscle atrophy after tumour induction. In contrast, subdiaphragmatic vagal deafferentation did not attenuate
cancer-induced anorexia or body weight loss. Tumour-bearing rats had substantially increased MIC-1 levels, which positively
correlated with tumour size and cancer progression and negatively correlated with food intake.
Conclusions These findings demonstrate the importance of the AP in the mediation of cancer-dependent anorexia and body
weight loss and support a pathological role of MIC-1 as a tumour-derived factor mediating CACS, possibly via an AP-dependent
action.
Keywords Cancer; Food intake; Energy balance; Brainstem; Muscle; AP-lesion; Subdiaphragmatic vagal deafferentation
Received: 3 August 2016; Revised: 26 September 2016; Accepted: 28 October 2016
*Correspondence to: Thomas Riediger, Institute of Veterinary Physiology, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland.
Email: triedig@vetphys.uzh.ch
Introduction
The anorexia-cachexia syndrome (ACS) is characterized by re-
duced eating and body weight loss, which is the consequence
of reduced fat and muscle mass.
1
More than 80% of patients
with advanced cancer suffer from loss of appetite and body
weight.
2
Cancer ACS (CACS) negatively affects the clinical sta-
tus, increases mortality, deteriorates treatment success, and
reduces quality of life.
3,4
Inflammatory signalling molecules
(e.g. cytokines) that are released during malignancy by the
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host immune system or by the tumour itself are important
mediators of CACS.5,6
The area postrema (AP) is a sensory circumventricular or-
gan of the caudal hindbrain, which is anatomically linked to
and interacts in a reciprocal manner with the nucleus tractus
solitarii (NTS).7 Because of the lack of a functional blood-brain
barrier, neurons of the AP represent targets for blood-borne
hormones and pathological signalling molecules. The AP ap-
pears to be involved in pathological anorexia because lesions
of the AP and the adjacent NTS region attenuate TNF-α-
induced anorexia in rats.8Moreover, AP neurons are activated
in tumour-bearing (TB) rats carrying hepatoma tumours.9
The NTS is an integrative relay centre for a variety of pe-
ripheral signals that control food intake.10 It is the main pro-
jection site of vagal afferents from the gastrointestinal tract
that transmits sensory visceral information to the brain. Va-
gotomy attenuated sickness-associated behaviours such as a
decrease in social exploration induced by IL-1β or by the in-
flammatory endotoxin lipopolysaccharide (LPS).11,12 On the
other hand, subdiaphragmatic vagal deafferentation (SDA)
failed to influence the anorectic effects of intraperitoneally
injected LPS, muramyl dipeptide or IL-1β, indicating that vagal
afferents are not necessary for the eating inhibition by these
inflammatory mediators.13,14 Experimental evidence for a role
of the AP or vagal afferents in cancer anorexia is scarce. The
only study addressing this question was conducted using a
rat Leydig cell tumour model, which is characterized by endo-
crine activity of oestrogens.15 Given that oestrogens act via
the AP/NTS regions to reduce food intake,16 the outcome of
that study may reflect the consequences of
hyperestrogenemia rather than specific tumour-dependent
signalling mechanisms. Moreover, the lesioning approach in
this study was not specific for the AP because the lesion in-
cluded major parts of the NTS, resulting in a destruction of va-
gal terminal fields. Therefore, knowledge about the general
role of the AP in cancer anorexia is very limited, and a better
dissociation between vagal and AP-dependent mechanisms
is required.
In the present study, we used neurosurgical approaches to
examine the role of the AP and vagal afferents in the media-
tion of cancer anorexia and body weight loss in a rat hepa-
toma tumour model. A vacuum aspiration approach allowing
the specific removal of the AP without compromising the
structural integrity the NTS was used.17 Moreover, we used
the SDA technique, which is the most sophisticated deafferen-
tation method because it disrupts all subdiaphragmatic vagal
afferents while leaving about 50% of vagal efferents intact.
The remaining vagal efferents are sufficient for maintaining
the control of gastrointestinal function.18 The comparison of
APX and SDA approaches allows for the dissociation of vagal
and AP mediated effects on CACS.
Despite their importance for disease-related anorexia, the
classic pro-inflammatory cytokines including interleukins,
TNF-α and IFN-γ do not seem to be required for the anorexia
in the hepatoma tumour model.
9,19
There is cumulating evi-
dence pointing to the AP as a target site for the signalling
molecule MIC-1, also known as growth differentiation factor
15 (GDF15). Tumour cell dependent expression of MIC-1
can increase serum levels by up to 100-fold.20–23 MIC-1 pro-
duced by xenografted tumours and recombinant protein both
reduce food intake and lead to cachectic body weight loss in
mice that can be inhibited by specific monoclonal antibod-
ies.24 Additionally, systemic injection of recombinant MIC-1
leads to rapid induction of c-Fos in the AP/NTS region, and
a lesion of this brain area blocks the anorectic effect of exog-
enous MIC-1 in mice.25 Given the recent evidence for a
hindbrain-dependent suppression of food intake by MIC-1
and to further support the importance of MIC-1 signalling in
CACS, we also sought to analyse MIC-1 blood levels at differ-
ent time points during cancer progression.
25
Materials and methods
Animals and housing conditions
Male Buffalo rats were used (Charles River Laboratory, USA).
The animals were housed at controlled temperature
(21 1 °C) under a 12-h artificial light cycle with ad libitum ac-
cess to standard laboratory rat chow (890 25W16, Provimi
Kliba, AG, Kaiseraugst, Switzerland). All experiments were ap-
proved by the Veterinary Office of the Canton Zurich.
Cell culture and tumour model
The hepatoma tumour model was described previously.9,26
Morris hepatoma 7777 cells (McA-RH7777, Catalog No. CRL-
1601, ATCC, USA) were cultured under standard conditions
in DMEM supplemented with 10% foetal bovine serum and
1% penicillin-streptomycin. Semi-confluent McA-RH7777
Petri dishes were washed with DMEM repeatedly to detach
the cells from the surface. After confirming viability of the
cells with trypan blue, 107 cells were inoculated subcutane-
ously between the scapulae in 250μL PBS under short
isoflurane anaesthesia. Control animals were also anaesthe-
tized and injected with PBS.
Area postrema lesion
The APX was conducted as described.27 Briefly, animals (200–
230 g) were placed in a stereotactic frame with the head
flexed ventrally in order to visualize the crista occipitalis.
The atlanto-occipital membrane was dissected, and the me-
ninges were carefully incised under surgical microscope con-
trol. The AP was then visualized and removed by vacuum
aspiration using a blunted 26G cannula connected to a water
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vacuum pump. The animals were allowed 2weeks for recov-
ery before the start of the behavioural trials.
A histological verification of successful AP lesion was per-
formed post-mortem. Microscopic coronal sections of the
AP/NTS region were analysed. Only those animals in which
the AP was removed without visible damage of the adjacent
NTS were included in the study. Photomicrographs were
taken at 20× magnification, using a Zeiss Imager Z2 micro-
scope fitted with a digital camera system (Zeiss Axiocam).
Subdiaphragmatic vagal deafferentation
This surgical technique consists in a left-side intracranial tran-
section of the vagal afferent rootlets and an ipsilateral tran-
section of the dorsal subdiaphragmatic trunk of the vagus
nerve resulting in complete SDA as previously described.
18
Rats (210–250 g) were pretreated with ip injections of
50μg/kg atropine, antibiotics, and then anaesthetized with
isoflurane. For sham-SDA surgery, the vagal rootlets and the
dorsal subdiaphragmatic vagus trunk were exposed without
disrupting them. Five millitre of warm saline and an analgesic
were injected ip after suturing the abdomen. Post-surgical
treatment with antibiotics and the analgesic continued for
the following 2 days.
Two histological tests aimed to verify the completeness of
SDA. These tests were based on published techniques for ret-
rograde labelling of vagal motor neurons in the dorsal motor
nucleus of the vagus (DMN) and anterograde labelling of va-
gal afferents in the NTS.28–30 Rats were anaesthetized with
isoflurane, and a midline incision at the level of the throat
was made to expose the left nodose ganglion. A glass micro-
pipette was inserted into the ganglion using a micromanipu-
lator. A water solution (1.5μL) containing the anterograde
tracer biotinylated dextran amine (BDA, 5%) and 1% blue
food colouring (Trawosa AG, St. Gallen, Switzerland) was
pressure injected (PicoSpritzer 3; Parker Instrumentation,
Fairfield, NJ) during 3–5min. Three days after surgery the an-
imals were shortly anaesthetized with isoflurane and 2mg of
the retrograde tracer fluorogold (FG) in 1mL saline (Fluoro-
chrome, Denver, CO) were injected intraperitoneally. After
2 days of tracer migration, the rats were perfused and the
brains were removed as described below. The procedure for
visualizing BDA-positive vagal projections in the NTS involved
an incubation with the avidin-biotin-peroxidase complex
followed by an incubation in 3,3′-diaminobenzidine solution
(0.05% 3,3′-diaminobenzidine, 0.009% H2O2, 0.04% NiCl2,
0.08% CoCl2 in 0.05M Tris-HCl). Absence of labelling was
interpreted as successful transection of vagal afferents. To
confirm completeness of unilateral subdiaphragmatic trunk
vagotomy, an observer who was blind to the rat’s surgery,
counted the number of fluorogold-labelled neurons in the left
and right DMN at the level of the AP. If the number of la-
belled cells found in the right DMN was less than 3% of the
number found in the left DMN, and if vagal afferent fibres
were absent in the NTS, the SDA surgery was considered suc-
cessful. Sham-SDA rats were only included if FG-positive
DMN neurons were labelled bilaterally and dense vagal affer-
ent terminals were detected histologically. Photomicrographs
were taken as described earlier.
Behavioural and metabolic studies
Using non-operated TB rats, we first sought to dissociate the
effects of tumour anorexia on body weight and muscle loss
from eating-independent effects. Non-tumour-bearing
(NTB), pair-fed (PF), and TB rats (220–250 g) were single-
housed in BIODAQ cages (Research Diets, NJ, USA) equipped
with an external food hopper allowing precise 24-h food in-
take measurements. Rats were adapted to the housing condi-
tions for 14 days before tumour cell injection. Daily food
intake and body weight were measured shortly before dark-
onset. Nine days after tumour induction, PF animals received
the same amount of food as was consumed the previous day
by the TB group. At the end of the experiment, the animals
were euthanized for blood and tissue collection.
We then assessed the impact of tumour growth on meta-
bolic rate and locomotor activity in this model. This experi-
ment, which involved TB and NTB rats (130–150 g), was
conducted in an open-circuit indirect calorimetric system
(TSE Phenomaster, Bad Homburg, Germany) equipped with
internal food hoppers and water bottles connected to scales,
which allow for continuous recording of food and water
consumption. The animals were single-housed in metabolic
cages and adapted to the housing conditions for 7 days be-
fore the start of the experiment. Body weight was measured
daily before dark onset. Food intake and respiratory gas ex-
change (O2 and CO2) were recorded automatically at 17-min
intervals throughout the entire experiment. Locomotor activ-
ity (i.e. number of horizontal movements) was recorded using
a frame of horizontal infrared beams (Accuscan, Columbus,
Ohio).
Behavioural and metabolic studies with APX and SDA rats
were also conducted in the same open-circuit indirect calori-
metric system. In both studies, the animals were kept and
adapted to the experimental conditions as described earlier.
Food intake and body weight were recorded daily.
Terminal tissue and blood collection
Rats were anaesthetized shortly before dark onset after injec-
tion of pentobarbital (100mg/kg ip). The thorax was opened
and blood was collected from the right ventricle for subse-
quent MIC-1 measurements. Immediately afterwards, the rats
were transcardially perfused with 0.1MPB followed by 4%
phosphate-buffered paraformaldehyde. The brains were
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removed, post-fixed for 4 h in 4% phosphate-buffered parafor-
maldehyde and then cryoprotected for 2 days in 20% sucrose
in 0.1MPB at 4°C. Brains were subsequently frozen in hexane.
Three series of coronal brainstem sections containing the
AP/NTS region (20μm) were cut with a cryomicrotome
(CM3050S, Leica Microsystems, Germany), thaw-mounted on
glass slides and then stored at 20°C until further processing.
MIC-1 measurements
Rats were single-housed in BIODAQ cages as described earlier.
Food intake and body weight were measured daily and tu-
mour growth was induced in all animals. Blood was obtained
by puncturing the sublingual vein under mild isoflurane an-
aesthesia. Sampling was conducted 3 days before tumour in-
duction (baseline) and 11 days and 17 days after induction,
that is, shortly after the onset of anorexia and during fully de-
veloped anorexia, respectively. Blood was collected in EDTA
containing tubes (Sarstedt, Nümbrecht, Germany) and centri-
fuged at 7000 × g (4°C, 7min) to obtain plasma, which was
stored in aliquots at80°C for subsequent analysis. The levels
MIC-1 were measured with using an ELISA (R&D Systems,
USA) according to the manufacturers’ instructions.
Body composition analysis and muscle and tumour
weight measurements
After euthanizing the rats, tumours were resected and
weighed. Total carcass lean and fat mass were measured by
magnetic resonance imaging (EchoMRI, Echo Medical Sys-
tems, Texas, USA). Two consecutive measurements were
taken to ensure instrument precision and averaged for the
subsequent statistical analysis. The left gastrocnemius,
tibialis, and soleus muscles were dissected at the level of
their upper to lower tendons and weighed.
Data evaluation and statistical analysis
Mean daily food intake, body weight, body composition (lean
and fat mass), and MIC-1 levels were expressed as
mean SEM. In the pair-feeding experiment, body weight
changes were calculated by subtracting the weight of the an-
imal at the day of tumour induction from the final body
weight. In the experiments involving AP-lesioned and
vagotomized animals, food intake was corrected for body
weight because at least in the APX study, the surgery had
an effect on body weight. This effect is in line with previous
studies in which APX animals tended to gain less weight than
sham-APX because of moderately decreased total food in-
take.17 Weekly body weight change after tumour-induction
was calculated by subtracting the body weight at the
beginning of each week from the body weight at the end of
same week. Food intake and body weight changes were quan-
tified across a 3-week period starting one week before the on-
set of anorexia. Presumably, because of general biological
variability, anorexia in the APX study started a week later than
in the SDA study, that is, 3 instead of 2weeks after tumour in-
duction. Metabolic rate was calculated from O2 consumption
and CO2 production as described previously.
31 Metabolic rate
data were normalized for body weight. The calculation was
based on the following equation: total EE (kcal/kg/h) =
(3.9 × VO2 + 1.1 × VCO2) / 1000. The average values obtained
between Days 1 and 3 after tumour inoculation were used
as baseline (i.e. prior to the onset of anorexia) and compared
with the average values during three consecutive days in each
week after tumour induction. The number of horizontal move-
ments (i.e. locomotor activity) was monitored across continu-
ous 5-min intervals over 24 h and expressed as average of
three consecutive days.
Statistical comparisons between multiple groups were per-
formed using one-way ANOVA followed by Tukey’s post-hoc
test. Unpaired Student’s t-test (two-sided) was used for com-
parison between two groups. Linear regression analysis was
used to examine the correlation between MIC-1 levels, tu-
mour weight and food intake. For all statistical tests, a P-
value less than 0.05 was considered significant. Data were
analysed using Prism GraphPad 5.0.
Results
Effects of tumour growth on food intake, body
weight and muscle, fat and lean mass
Tumours became palpable between Days 9 and 11, which co-
incided with the onset of the anorectic response. TB rats
showed significantly lower food intake than NTB animals from
Day 11 after tumour cell inoculation. Daily food intake stabi-
lized at a lower level with an average reduction of 45% in com-
parison to NTB animals (Figure 1A). While NTB animals
displayed constant body weight gain during the experimental
period, TB animals showed a marked loss of body weight,
which became significant 12 days after tumour induction.
Pair-feeding reduced body weight gain, which led to a signifi-
cantly lower body weight compared with NTB on Days 18–
19. Pair-feeding did not, however, lower body weight to the
level of the TB animals; these animals were significantly
heavier than the TB rats on Day 13 (Figure 1B–C). TB animals
had lower lean carcass mass in comparison with healthy con-
trols and PF animals (Figure 1D). TB rats also had lower fat
mass than controls and PF rats. Furthermore,TB rats had lower
gastrocnemius and tibialis muscle mass than NTB animals
(Figure 1E), while muscle weight of the PF group did not differ
from NTB controls. The tumour weight was 13.2 1.5 g at the
end of experiment.
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Effects of tumour growth on metabolism and
locomotor activity
Energy expenditure and activity were analysed in a separate
cohort of TB and NTB rats. The food intake of these animals
following tumour induction decreased, leading to significantly
lower body weight in TB rats compared to NTB controls
(Figure 2A–B). While the metabolic rate of the NTB controls
did not significantly change during the experiment, TB animals
showed a slight but significant reduction in metabolic rate
during the third week after tumour induction (Figure 2C).
Daily locomotor activity was similar between the two experi-
mental groups (Figure 2D) and there were no differences in
the diurnal and nocturnal activity pattern (data not shown).
Area postrema lesion blocked anorexia and
attenuated tumour-induced body weight loss and
muscle degradation
Body weight before tumour induction was lower in the APX
animals compared with sham-APX rats (APX: 225 9 vs.
sham-APX 262 8.5 g). However, no significant differences
in food intake between the experimental groups occurred
prior to tumour anorexia when food intake was corrected
for body weight (APX: 7.2 0.2 vs. sham-APX: 7.6 0.2 g/
100 g BW). The food intake of the sham-APX rats decreased
following tumour induction, resulting in a significant reduc-
tion of 40 3% between Weeks 2 and 4 (Figure 3A). This ef-
fect was accompanied by a decline in body weight gain,
leading to net body weight loss in Week 4 (Figure 3B). Strik-
ingly, and in contrast to its effect in sham-APX rats, tumour
growth did not affect food intake in APX animals (Figure 3A).
The weekly body weight gain of the APX rats only significantly
decreased in Week 4. In contrast to sham-APX rats, however,
APX animals did not lose body weight following tumour
growth (Figure 3B). Furthermore, APX rats had higher gastroc-
nemius and soleus muscle weights than controls (Figure 3C).
The metabolic rate was similar between APX and sham-APX
animals. Tumour growth decreased metabolic rate in both
surgical groups similarly with a significant reduction between
Weeks 2 and 3. No further decrease occurred between Weeks
3 and 4 (APX vs. sham-APX, wk2: 185.8 10.3 vs. 186.1 5.4;
wk3: 160.6 2.6, 160.0 1.3; wk4: 162.2 4.8 vs.
159.6 3.4 kcal/kg/d). Locomotor activity was similar in APX
and sham-APX animals and no significant changes occurred
between the two groups following tumour induction (APX
vs. sham-APX, wk2: 5.5 0.5 vs. 5.6 0.4; wk3: 6.6 0.4 vs.
Figure 1 Tumour-induced body weight loss and muscle degradation are partly independent of anorexia. (A–C) Tumour-bearing rats developed an-
orexia and lost body weight. Pair-feeding only led to an attenuation of body weight gain that was calculated by subtracting the body weight at the
time of tumour induction from the body weight at the end of the experiment. (D) Tumour-bearing animals had lower lean and fat carcass mass com-
pared with both control groups. (E) Tumour-bearing rats had lower gastrocnemius and tibialis muscle mass compared with Non-Tumour-bearing an-
imals and lower gastrocnemius muscle mass compared with the pair-fed group. Data analysed with Student’s t-test (A) or with one-way ANOVA
followed by Tukey’s post-hoc test (B–E). Means with different letter or symbols are significantly different from each other; * P< 0.05, ** P< 0.01,
*** P< 0.001, same for # and §).
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6.7 0.5; wk4: 6.0 0.5 vs. 6.7 0.3 arbitrary units). Impor-
tantly, tumour weight did not differ significantly between
APX and sham-APX rats at the end of the experiment
(9.6 0.7 vs. 7.7 2.3 g). Representative histological sections
of the AP/NTS region from a sham-APX and an APX animal are
shown in Figure 3D.
Subdiaphragmatic vagal deafferentation did not
prevent tumour-induced anorexia and body weight
loss
In line with previous reports, daily food intake did not differ
between SDA and sham-SDA animals prior to tumour induc-
tion (21.8 0.9 SDA vs. 22.3 0.5 g sham-SDA).32,33 More-
over, body weight did not differ between the two groups
before the surgery (SDA: 253 4 vs. sham-SDA: 246 3 g)
and prior to tumour induction (SDA: 252 5 vs. sham-SDA:
248 4 g). In contrast to APX, SDA did not affect tumour-
induced anorexia. Tumour growth reduced food intake in
SDA and sham-SDA rats similarly, leading to a food intake re-
duction of 39 3 and 41 2% between Weeks 1 and 3 in
SDA and sham-SDA rats, respectively (Figure 4A). Likewise,
tumour growth attenuated body weight gain in both groups
during Week 2 similarly, resulting in body weight loss in Week
3 (Figure 4B). No differences in lean and fat mass, metabolic
rate, and locomotor activity were observed between the two
groups (data not shown). The tumour weight of the SDA and
sham-SDA animals did not differ at the end of the experiment
(17.6 2.6 vs. 21.8 1.9 g). Figure 4C shows representative
histological sections of animals in both groups. Unilateral an-
terograde labelling of vagal afferents in the NTS was visible in
sham-SDA but absent in SDA rats. Furthermore, sham-SDA
rats showed bilateral retrograde labelling of vagal motor neu-
rons in the DMN, whereas only unilateral staining of the DMN
was present in SDA animals.
Tumour growth and anorexia correlated with
MIC-1 blood levels
MIC-1 plasma levels in TB rats were significantly higher than
in NTB and PF controls at the end of the experiment, showing
a 42-fold increase (Figure 5A). MIC-1 levels did not differ be-
tween PF and NTB rats. In a separate group of animals, MIC-1
Figure 2 Tumour growth reduced metabolic rate without affecting locomotor activity. Tumour-bearing rats developed anorexia (A) and showed re-
duced body weight gain (B), but did not show differences in metabolic rate (C) or locomotor activity (D), except during Week 3 in which tumour-bear-
ing rats showed reduced metabolic rate. Data analysed with Student’s t-test (A–B), * P< 0.05, ** P< 0.01, *** P< 0.001. Data analysed with one-way
ANOVA followed by Tukey’s post-hoc test (C–D). Means with different letters are significantly different from each other (P< 0.05).
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levels were also measured before tumour induction, shortly
after the onset of anorexia and at the end of the experiment
(11 and 17 days after tumour induction, respectively). MIC-1
plasma levels were already elevated 11 days after tumour in-
duction compared with baseline conditions and increased
further until Day 17 (Figure 5B). MIC-1 levels positively corre-
lated with tumour size (Figure 5C) and with the severity of
anorexia during tumour growth (Figure 5D).
Discussion
The role of the AP and of vagal afferents in chronic cancer an-
orexia and body weight loss has neither been critically exam-
ined nor conclusively dissociated. Using the specific APX and
SDA approaches, we now provide evidence that the AP is re-
quired for cancer anorexia and body weight loss in hepatoma
TB rats. Lesion of the AP also attenuated cancer-dependent
muscle loss. In contrast to APX, SDA did not affect cancer-
induced anorexia and body weight loss, indicating that vagal
afferents are not necessary for the mediation of CACS in this
model. We also identified MIC-1 as a possible mediator of
CACS in hepatoma TB rats because MIC-1 levels correlated
with tumour progression and tumour size, and correlated
negatively with food intake.
As demonstrated in previous studies, hepatoma TB rats
showed an activation of the AP/NTS region that was caused
by tumour growth but not as a consequence of anorexia be-
cause it did not occur in pair-fed NTB controls.9 Our studies
extend this observation by demonstrating clear differences
between TB and pair-fed NTB rats with respect to body
weight, body composition, and muscle mass. TB rats lost con-
siderably more body weight than NTB pair-fed rats and
showed a reduction in total lean mass and hind limb muscle
mass. These findings are consistent with the notion that
Figure 3 Lesion of the area postrema attenuated anorexia, body weight loss and muscle degradation induced by tumour growth. (A–B) Area postrema
lesioned (APX) animals were protected against tumour-induced anorexia and showed markedly attenuated body weight loss following tumour induc-
tion. (C) Area postrema lesioned rats show higher gastrocnemius and soleus mass compared to area postrema-sham lesioned (sham-APX)
tumour-bearing animals. (D) Coronal sections of the area postrema/nucleus tractus solitarii of a sham-lesioned control (upper image) and an area
postrema lesioned animal (lower image). AP, area postrema; NTS, nucleus tractus solitarii; DMN, dorsal motor nucleus of the vagus; Gr, gracile nucleus;
CC, central canal. Data analysed with one-way ANOVA followed by Tukey’s post-hoc test (A–B), means with different letters are significantly different
from each other (P< 0.05). Changes in food intake, differences in body weight change between Weeks 2 and 4, and muscle weights were analysed
using the Student’s t-test (A-C), * P< 0.05, ** P< 0.01, *** P< 0.001.
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tumour-dependent body weight loss and muscle degradation
is not only due to reduced energy intake.
Differences in metabolic rate and locomotor activity be-
tween TB and NTB were small or absent, respectively. The
only significant difference consisted of a reduced metabolic
rate of TB rats during Week 3 after tumour induction. The
consequences of cancer growth for energy expenditure vary
among tumour models depending on the status of inflamma-
tion and effects caused by changes in food intake or physical
activity.34,35 In our studies, the moderately reduced meta-
bolic rate of TB rats might be related to the reduced food
intake.
Notably, indirect calorimetry does not reflect possible
changes in energy expenditure because of anaerobic metab-
olism, which particularly occurs in tumour tissues, including
the hepatoma cells used in these studies.36,37 The consider-
ably greater body weight loss in TB vs. pair-fed NTB rats in
the absence of marked differences in aerobic metabolic rate
and locomotor activity suggests a role of anaerobic hyperme-
tabolism in this tumour model. Another possible reason for
the difference in body weight between TB and PF animals
could be related to a maladaptation of energy expenditure,
following reduced caloric intake. Reduction in metabolic rate
during food-restriction is a well-known adaptive mechanism
Figure 4 Subdiaphragmatic vagal deafferentation did not attenuate cancer-anorexia-cachexia syndrome. (A) Tumour growth induced a strong anorec-
tic response in both subdiaphragmatic vagal deafferentation (SDA) and sham-operated (sham-SDA) animals. (B) In both groups anorexia was paralleled
by a similar reduction of body weight gain in Week 2 and a net body weight loss in Week 3. (C) Schematic illustration of afferent and efferent vagal
fibres targeted by the subdiaphragmatic vagal deafferentation and of the procedures used to verify its completeness. The subdiaphragmatic vagal de-
afferentation consists in a left intracranial rhizotomy of all dorsal vagal fibres (i.e. afferent) (1) and a complete subdiaphragmatic dissection (afferent
and efferent fibers) of the left trunk of the vagus nerve (2). With this surgical procedure all vagal afferents are dissected, leaving 50% of the vagal
efferents intact. Biotinylated dextran amine (BDA) was applied directly into the nodose ganglion of the vagus nerve 5 days prior to sacrifice (3).
Fluorogold (FG) was injected intraperitoneally 48 h prior to sacrifice (4). D–E) Coronal sections of the area postrema/nucleus tractus solitarii region
of a sham-lesioned control and a subdiaphragmatic vagal deafferentation animal. (D) While biotinylated dextran amine-positive fibers were present
in the nucleus tractus solitarii of sham rats, no labelling was observed in the nucleus tractus solitarii of subdiaphragmatic vagal deafferentation
animals. (E) While bilateral Fluorogold staining in the dorsal motor nucleus (DMN) of sham rats was observed, only unilateral staining of the dorsal
motor nucleus occurred in subdiaphragmatic vagal deafferentation animals. CC, central canal. One-way ANOVA followed by Tukey’s post-hoc test,
means with different letters are significantly different from each other (P< 0.05).
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preventing excessive body weight loss. While this mechanism
might have partially protected PF animals from body weight
loss, an adaptive reduction in metabolic rate might have been
negligible in TB rats.38,39 We did not directly compare meta-
bolic rate of PF and TB rats, but the small reduction in meta-
bolic rate of TB rats compared with NTB animals is in line with
this assumption.
In contrast to earlier studies using AP/NTS lesions, the NTS
was not lesioned in our study.15 This is important because it
means that the neuroanatomy conveying vagal afferent sig-
nalling to the hindbrain was still intact in our APX study. Fur-
thermore, by using SDA, we minimized the severe
impairment of gastrointestinal function that usually occurs
in other experimental approaches (e.g. complete
subdiaphragmatic vagotomy). Although lesion of the AP mod-
erately reduces food intake and body weight compared with
controls,17,27 APX animals are still sensitive to anorectic stim-
uli such as LPS or CCK.40,41 Therefore, lesion of the AP does
not create a state of general unresponsiveness to anorectic
stimuli. While APX rats did not develop cancer anorexia or
body weight loss, body weight gain significantly decreased in
the last week of the experiments. As discussed earlier, anaer-
obic hypermetabolism might have contributed to reduced
body weight gain. Furthermore, mean daily food intake
tended to decrease during the last week leading to a non-
significant reduction of cumulative food intake by about 10 g
compared with the week before. We did not attempt to con-
firm or exclude the possible reasons for the reduced body
weight gain toward the end of the experiment because the
different effects mentioned earlier are likely to act in concert.
Most importantly, however, our studies clearly demon-
strate an amelioration of CACS in APX rats including an atten-
uation of muscle loss. Differences in tumour growth did not
account for decreased loss of muscle mass, because APX did
not affect the tumour size. The lesion of the AP per se is also
unlikely to increase muscle mass because APX rats generally
tend to have lower body weights compared with sham-APX
rats. The pathological mechanisms leading to muscle wasting
in the present tumour model have not yet been explored. In
general, pro-inflammatory cytokines are important mediators
of cancer-dependent muscle wasting acting via muscle degra-
dation pathways.42 So far, no increased levels of TNF-α, IL-1β,
IL-6, or IFN-γ have been identified in this tumour model.9 TB
APX rats might be able to partially preserve muscle mass be-
cause of higher energy intake than TB sham-APX rats, but
pair-feeding experiments would be required to confirm this.
The persistence of CACS in SDA rats may seem surprising
given the presumed role of vagal afferents for the transmis-
sion of sickness-related signals to the brain.43 While the
SDA approach is the most appropriate surgical technique to
disrupt vagal afferent signalling, we cannot exclude that af-
ferent signals originating from the right nodose ganglion
could be transmitted to the brainstem. However, the effects
of anorectic stimuli such as CCK are blocked by SDA, suggest-
ing that an intact nodose ganglion is not sufficient for the
suppression of food intake induced by vagus-dependent ano-
rectic stimuli.44 Based on almost identical anorexia and body
weight loss in SDA compared with sham-SDA animals, it ap-
pears unlikely that the full CACS response is mediated via a
unilateral supradiaphragmatic vagal mechanism.
Whereas in some studies, complete subdiaphragmatic va-
gotomy has been shown to reduce different sickness-related
symptoms including LPS and IL-1β-induced anorexia,45 the
more specific SDA procedure that we employed here did
not attenuate the anorectic response to immunomodula-
tors.
13,14
Moreover, all these studies investigated the involve-
ment of the vagus nerve in sickness anorexia accompanying
acute models of inflammation, for example, treatment with
endotoxins such as LPS or muramyl dipeptide or acute injec-
tion of pro-inflammatory cytokines. To our knowledge, the
only study exploring the role of the vagus in cancer anorexia
was conducted in Leydig cell TB rats. Both total vagotomy
and capsaicin-induced vagal damage attenuated tumour an-
orexia in this tumour model.46 Whether the vagal mediation
Figure 5 Macrophage inhibitory cytokine-1 levels increased with tumour progression and correlated with tumour size and the severity of anorexia (A)
macrophage inhibitory cytokine-1 plasma levels were significantly higher in tumour-bearing rats compared to controls at the end of the experiment.
(B) macrophage inhibitory cytokine-1 levels were elevated 11 days after tumour induction (i.e. 3 days after anorexia onset) and further increased with
cancer progression. (C) Macrophage inhibitory cytokine-1 levels correlated with tumour weight. (D) Macrophage inhibitory cytokine-1 levels negatively
correlated with food intake during tumour growth. Data analysed with one-way ANOVA followed by Tukey’s post-hoc test (A–B), means with different
letters are significantly different from each other (P< 0.05).
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of cancer anorexia in this model is related to oestrogen pro-
duced by the tumour remains unclear but represents a plau-
sible explanation.
Overall, the heterogeneity of findings regarding the in-
volvement of vagal afferent signalling in disease-related an-
orexia may reflect differences in pathological characteristics
of the pertinent disease models. Although we cannot gener-
alize our finding that vagal afferents did not contribute to
cancer anorexia, the clear-cut dissociation of vagal vs. AP-
dependent mechanisms helps to narrow down possible
pathomechanisms and therapeutic targets.
There is much evidence for the pivotal role of pro-
inflammatory cytokines in the development of CACS.47 In
contrast to other tumour models,48 no increases in circulating
cytokines such as IL-1β, IFN-γ, IL-6, and TNF-α have been ob-
served in hepatoma TB rats.9 We therefore hypothesized that
other cytokines or tumour-derived factors might contribute
to CACS in this tumour model. Consistent with this hypothe-
sis, we identified clearly elevated levels of MIC-1 in TB rats,
which positively correlated with tumour size and anorexia.
The increase in circulating MIC-1 was not secondary to an-
orexia because pair-fed NTB rats had basal MIC-1 levels com-
parable with ad libitum fed controls. This finding parallels
recent observations in humans demonstrating that MIC-1
levels do not seem to be determined by the amount of food
intake.49 Different types of tumours express high levels of
MIC-1.21–23 Under inflammatory conditions, MIC-1 can also
be expressed by host tissue.
50
While we have not identified
the origin of MIC-1 in TB rats, the lack of a general elevation
in pro-inflammatory cytokines and the strong correlation be-
tween tumour size and MIC-1 levels suggest the tumour as a
likely source of MIC-1 in hepatoma TB rats.
Our studies complement previous findings suggesting that
MIC-1 contributes to CACS via an AP/NTS-dependent action
as MIC-1-induced anorexia and body weight loss was attenu-
ated in mice with AP/NTS lesion.25 While only a combined
AP/NTS lesion completely blunted the effect of MIC-1
treatment on body weight, mice with specific lesions of the
AP showed reduced body weight gain but were protected
against body weight loss.
The clinical relevance of MIC-1 as a possible mediator of
CACS in humans has primarily been evaluated based on cor-
relations of MIC-1 blood levels with tumour and disease pa-
rameters (e.g. body weight loss). While in many clinical
studies MIC-1 levels correlated with the severity of body
weight loss in cancer patients,24,51 other studies did not ob-
serve such a correlation.
52,53
Several clinical studies
highlighted the potential use of MIC-1 as a biological marker
for prognosis and diagnosis of certain types of cancer52,54,55
(see Fairlie et al.
56
for review). It is important to highlight that
the clinical relevance of MIC-1 in human cancer patients ap-
pears to vary depending on the type of cancer.
Collectively, our studies substantiate the role of the AP in
CACS. We also identified MIC-1 as a possible humoral media-
tor of anorexia and body weight loss in hepatoma TB rats.
Both MIC-1 and local signalling processes in the AP/NTS re-
gion (e.g. GLP-1) represent promising therapeutic targets
for the treatment of CACS.
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